{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,2]],"date-time":"2026-08-02T23:24:15Z","timestamp":1785713055442,"version":"3.56.0"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,9,15]],"date-time":"2022-09-15T00:00:00Z","timestamp":1663200000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004324","name":"Astellas Pharma US","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004324","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007054","name":"Meso Scale Diagnostics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004215","name":"Pantarhei Bioscience BV","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004215","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004622","name":"KWF Kankerbestrijding","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004622","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Open Science"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.euros.2022.09.006","type":"journal-article","created":{"date-parts":[[2022,10,3]],"date-time":"2022-10-03T13:01:26Z","timestamp":1664802086000},"page":"59-67","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Estetrol Prevents Hot Flushes and Improves Quality of Life in Patients with Advanced Prostate Cancer Treated with Androgen Deprivation Therapy: The PCombi Study"],"prefix":"10.1016","volume":"45","author":[{"given":"Yvette","family":"Zimmerman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Frydenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hendrik","family":"van Poppel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. Jeroen A.","family":"van Moorselaar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik P.M.","family":"Roos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diederik M.","family":"Somford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ton A.","family":"Roeleveld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tjard D.","family":"de Haan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harm H.E.","family":"van Melick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yacov","family":"Reisman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Krijgh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frans M.J.","family":"Debruyne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herjan J.T.","family":"Coelingh Bennink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euros.2022.09.006_b0005","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/j.annonc.2020.06.011","article-title":"Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"31","author":"Parker","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.euros.2022.09.006_b0010","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s40487-020-00119-z","article-title":"Metastatic hormone-sensitive prostate cancer (mHSPC): advances and treatment strategies in the first-line setting","volume":"8","author":"Ng","year":"2020","journal-title":"Oncol Ther"},{"key":"10.1016\/j.euros.2022.09.006_b0015","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1210\/endrev\/bnab002","article-title":"Hormonal therapy for prostate cancer","volume":"42","author":"Desai","year":"2021","journal-title":"Endocr Rev"},{"key":"10.1016\/j.euros.2022.09.006_b0020","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.eururo.2020.09.046","article-title":"EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer. Part II\u20142020 update: treatment of relapsing and metastatic prostate cancer","volume":"79","author":"Cornford","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.euros.2022.09.006_b0025","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1172\/JCI125755","article-title":"Impact of estrogens in males and androgens in females","volume":"129","author":"Hammes","year":"2019","journal-title":"J Clin Invest"},{"key":"10.1016\/j.euros.2022.09.006_b0030","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.maturitas.2009.10.017","article-title":"Managing hot flushes in men after prostate cancer\u2014a systematic review","volume":"65","author":"Frisk","year":"2010","journal-title":"Maturitas"},{"key":"10.1016\/j.euros.2022.09.006_b0035","first-page":"163","article-title":"Estrogenic side effects of androgen deprivation therapy","volume":"9","author":"Guise","year":"2007","journal-title":"Rev Urol"},{"key":"10.1016\/j.euros.2022.09.006_b0040","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/pcan.2009.35","article-title":"Androgen deprivation therapy and estrogen deficiency induced adverse effects in the treatment of prostate cancer","volume":"12","author":"Freedland","year":"2009","journal-title":"Prostate Cancer Prostat Dis"},{"key":"10.1016\/j.euros.2022.09.006_b0045","first-page":"463","article-title":"Unique effects on hepatic function, lipid metabolism, bone and growth endocrine parameters of estetrol in combined oral contraceptives","volume":"20","author":"Mawet","year":"2015","journal-title":"Eur J Contracept Reprod Health Care"},{"key":"10.1016\/j.euros.2022.09.006_b0050","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.contraception.2020.08.015","article-title":"Evaluation of the effect of a new oral contraceptive containing estetrol and drospirenone on hemostasis parameters","volume":"102","author":"Douxfils","year":"2020","journal-title":"Contraception"},{"issue":"Suppl 1","key":"10.1016\/j.euros.2022.09.006_b0055","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1080\/13697130701798692","article-title":"Oral bioavailability and bone-sparing effects of estetrol in an osteoporosis model","volume":"11","author":"Coelingh Bennink","year":"2008","journal-title":"Climacteric"},{"key":"10.1016\/j.euros.2022.09.006_b0060","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.euros.2021.04.005","article-title":"Estetrol cotreatment of androgen deprivation therapy in infiltrating or metastatic, castration-sensitive prostate cancer: a randomized, double-blind, phase II trial (PCombi)","volume":"28","author":"Coelingh Bennink","year":"2021","journal-title":"Eur Urol Open Sci"},{"key":"10.1016\/j.euros.2022.09.006_b0065","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1080\/17512433.2022.2054413","article-title":"Profile of estetrol, a promising native estrogen for oral contraception and the relief of climacteric symptoms of menopause","volume":"15","author":"Gerard","year":"2022","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"Suppl 1","key":"10.1016\/j.euros.2022.09.006_b0070","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1080\/13697130802073425","article-title":"Estetrol review: profile and potential clinical applications","volume":"11","author":"Coelingh Bennink","year":"2008","journal-title":"Climacteric"},{"key":"10.1016\/j.euros.2022.09.006_b0075","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1159\/000503095","article-title":"Performance status assessment by using ECOG (Eastern Cooperative Oncology Group) score for cancer patients by oncology healthcare professionals","volume":"12","author":"Azam","year":"2019","journal-title":"Case Rep Oncol"},{"key":"10.1016\/j.euros.2022.09.006_b0080","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1016\/S0090-4295(97)00459-7","article-title":"Measuring quality of life in men with prostate cancer using the Functional Assessment of Cancer Therapy-Prostate instrument","volume":"50","author":"Esper","year":"1997","journal-title":"Urology"},{"key":"10.1016\/j.euros.2022.09.006_b0085","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1111\/j.1524-4733.2008.00409.x","article-title":"Estimating clinically meaningful changes for the Functional Assessment of Cancer Therapy-Prostate: results from a clinical trial of patients with metastatic hormone-refractory prostate cancer","volume":"12","author":"Cella","year":"2009","journal-title":"Value Health"},{"key":"10.1016\/j.euros.2022.09.006_b0090","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1002\/pros.23967","article-title":"Optimizing the role of androgen deprivation therapy in advanced prostate cancer: challenges beyond the guidelines","volume":"80","author":"Shore","year":"2020","journal-title":"Prostate"},{"key":"10.1016\/j.euros.2022.09.006_b0095","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1038\/pcan.2011.11","article-title":"Hot flushes in prostatic cancer patients during androgen-deprivation therapy with monthly dose of degarelix or leuprolide","volume":"14","author":"Iversen","year":"2011","journal-title":"Prostate Cancer Prostat Dis"},{"key":"10.1016\/j.euros.2022.09.006_b0100","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.eururo.2020.03.001","volume":"78","author":"Dearnaley","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.euros.2022.09.006_b0105","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1056\/NEJMoa2004325","article-title":"Oral relugolix for androgen-deprivation therapy in advanced prostate cancer","volume":"382","author":"Shore","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euros.2022.09.006_b0110","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1111\/j.1442-2042.2004.00896.x","article-title":"Influence of hot flashes on quality of life in patients with prostate cancer treated with androgen deprivation therapy","volume":"11","author":"Nishiyama","year":"2004","journal-title":"Int J Urol"},{"key":"10.1016\/j.euros.2022.09.006_b0115","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/S1470-2045(13)70025-1","article-title":"Cardiovascular outcomes in patients with locally advanced and metastatic prostate cancer treated with luteinising-hormone-releasing-hormone agonists or transdermal oestrogen: the randomised, phase 2 MRC PATCH trial (PR09)","volume":"14","author":"Langley","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euros.2022.09.006_b0120","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1111\/bju.13687","article-title":"Quality-of-life outcomes from the Prostate Adenocarcinoma: TransCutaneous Hormones (PATCH) trial evaluating luteinising hormone-releasing hormone agonists versus transdermal oestradiol for androgen suppression in advanced prostate cancer","volume":"119","author":"Gilbert","year":"2017","journal-title":"BJU Int"},{"key":"10.1016\/j.euros.2022.09.006_b0125","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/s41391-018-0081-6","article-title":"Estrogens and prostate cancer","volume":"22","author":"Dobbs","year":"2019","journal-title":"Prostate Cancer Prostat Dis"},{"key":"10.1016\/j.euros.2022.09.006_b0130","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.ucl.2005.12.008","article-title":"Managing complications of androgen deprivation therapy for prostate cancer","volume":"33","author":"Holzbeierlein","year":"2006","journal-title":"Urol Clin North Am"},{"key":"10.1016\/j.euros.2022.09.006_b0135","first-page":"687","article-title":"Endocrine complications of androgen-deprivation therapy in men with prostate cancer","volume":"4","author":"Harle","year":"2006","journal-title":"Clin Adv Hematol Oncol"},{"key":"10.1016\/j.euros.2022.09.006_b0140","doi-asserted-by":"crossref","first-page":"662","DOI":"10.2214\/ajr.117.3.662","article-title":"Pre-estrogen irradiation of the breast to prevent gynecomastia","volume":"117","author":"Cook","year":"1973","journal-title":"Am J Roentgenol"},{"key":"10.1016\/j.euros.2022.09.006_b0145","first-page":"E86","article-title":"Comparing interventions for management of hot flashes in patients with breast and prostate cancer: a systematic review with meta-analyses","volume":"47","author":"Hutton","year":"2020","journal-title":"Oncol Nurs Forum"},{"key":"10.1016\/j.euros.2022.09.006_b0150","first-page":"63","article-title":"Androgen deprivation therapy for prostate cancer: long-term safety and patient outcomes","volume":"5","author":"Ahmadi","year":"2014","journal-title":"Patient Relat Outcome Meas"},{"key":"10.1016\/j.euros.2022.09.006_b0155","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.eururo.2014.06.011","article-title":"Selective estrogen receptor alpha agonist GTx-758 decreases testosterone with reduced side effects of androgen deprivation therapy in men with advanced prostate cancer","volume":"67","author":"Yu","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.euros.2022.09.006_b0160","doi-asserted-by":"crossref","first-page":"T119","DOI":"10.1530\/ERC-13-0467","article-title":"Androgen deprivation therapy complications","volume":"21","author":"Allan","year":"2014","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.euros.2022.09.006_b0165","doi-asserted-by":"crossref","first-page":"3239","DOI":"10.1210\/jc.2018-00147","article-title":"A dose-escalating study with the fetal estrogen estetrol in healthy men","volume":"103","author":"Coelingh Bennink","year":"2018","journal-title":"J Clin Endocrinol Metab"}],"container-title":["European Urology Open Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666168322019061?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666168322019061?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T20:08:05Z","timestamp":1762978085000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666168322019061"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":33,"alternative-id":["S2666168322019061"],"URL":"https:\/\/doi.org\/10.1016\/j.euros.2022.09.006","relation":{},"ISSN":["2666-1683"],"issn-type":[{"value":"2666-1683","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Estetrol Prevents Hot Flushes and Improves Quality of Life in Patients with Advanced Prostate Cancer Treated with Androgen Deprivation Therapy: The PCombi Study","name":"articletitle","label":"Article Title"},{"value":"European Urology Open Science","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euros.2022.09.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier B.V. on behalf of European Association of Urology.","name":"copyright","label":"Copyright"}]}}